Sino Biopharmaceutical Chairwoman Theresa Tse confirmed the company's aggressive M&A strategy during a recent interview. Following a newly announced buyout, she stated the firm remains actively seeking additional acquisitions of Chinese biotech firms. Tse also revealed parallel efforts to secure partnerships with major multinational corporations, signaling a two-pronged expansion approach.

This strategy reflects the broader consolidation trend within China's domestic pharmaceutical sector. With government policy encouraging innovation and reducing market fragmentation, larger players like Sino Biopharm are positioned to absorb smaller, research-heavy outfits. This move helps them build a more comprehensive product pipeline to compete both locally and against international giants entering the market.

Investors will now watch for specific targets Sino Biopharm may pursue in the coming months. The hunt for multinational partners suggests a desire for global expertise and market access, not just domestic scale. Successfully integrating these new assets and alliances will be the true test of Tse's ambitious growth plan for the company.